课题基金 / 基金详情

Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response

Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response
雌激素受体在狼疮炎症反应调节剂中的作用
批准号：
7904900
负责人：
Gary S Gilkeson
金额：
$0.0万
依托单位：
RALPH H JOHNSON VA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-10-01 至 2013-09-30
来源：
https://reporter.nih.gov/project-details/7904900
关键词：
AddressAffectAgonistAnti-Inflammatory AgentsAnti-inflammatoryAntigen-Antibody ComplexAreaAutoantibodiesAutoimmune DiseasesB-Cell ActivationB-LymphocytesBackcrossingsBindingBiological PreservationBone Marrow TransplantationCCL2 geneCalcineurinCaringCell CountCell LineCell NucleusCellsClinicCongenic MiceDevelopmentDiseaseEpigenetic ProcessEstrogen Receptor alphaEstrogen ReceptorsEstrogensFamilyFemaleFundingGenderGenesGenotypeGlomerulonephritisGonadal Steroid HormonesHormone ReceptorIL6 geneImmuneImmune responseImmunityImmunoglobulin GIn VitroInflammationInflammatory ResponseKidneyKidney DiseasesKidney FailureKnock-outLigand BindingLigandsLupusLupus NephritisMediatingMediator of activation proteinMedicalMinorityMolecularMusNZW MouseNuclear Hormone ReceptorsNuclear TranslocationOrganPathogenesisPathologicPathway interactionsPatientsPhosphorylationPhysiologicalPopulationPrevalenceProductionPromoter RegionsProteinuriaPublicationsReceptor SignalingRenal functionResearchResponse ElementsRoleSLEB1 geneSerumSex CharacteristicsSex ChromosomesSignal TransductionSmall Interfering RNASomatic MutationSystemic Lupus ErythematosusT-LymphocyteTLR3 geneTestingTissuesToll-Like Receptor 2Toll-like receptorsTumor Necrosis Factor-alphaVeteransWomanX Inactivationabstractinganti-dsDNA antibodiesbasecell typecongenicexpectationhuman TNF proteinin vivoinsightinterestlupus prone micemacrophagemalemenmesangial cellmortalitymutantnew therapeutic targetnovelnovel strategiespromoterprotective effectpublic health relevancereceptorreceptor expressionresponsesle1/sle3 gene

项目成果

Gary S Gilkeson的其他基金

相似基金

相关文献

期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
Improving Minority Health in Rheumatic Diseases
Improving Minority Health in Rheumatic Diseases
海外基金